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OBJECTIVE—Ginsenganditsactivecomponent,ginsenosideRe,arepopularherbalproducts
thatare advocated for treatment of diabetes.Thepurpose of thisstudywas to determine whether
ginsengorginsenosideReimprovesb-cellfunctionandinsulinsensitivity(IS)ininsulin-resistant
subjects.
RESEARCH DESIGN AND METHODS—Overweight or obese subjects (BMI = 34 6 1
kg/m
2) with impaired glucose tolerance or newly diagnosed type 2 diabetes were randomized to
30 days of treatment with ginseng root extract (8 g/day), ginsenoside Re (250–500 mg/day), or
placebo.b-Cellfunctionwasassessedasthedispositionindex(DI)andmeasuredbyafrequently
sampled oral glucose tolerance test, and IS was assessed as the relative increase in glucose disposal
during a hyperinsulinemic-euglycemic clamp procedure plus stable isotope tracer infusion.
RESULTS—Values for DI and IS after therapy (Post) were not different from values before
therapy (Pre) in the placebo (DI: Pre, 5.8 6 0.9 3 10
23 and Post, 5.8 6 0.8 3 10
23, P = 0.99;
IS: Pre,165629%andPost,185624%,P=0.34),ginseng(DI:Pre,7.762.0310
23andPost,
6.0 6 0.83 10
23, P = 0.29;IS: Pre, 171 6 72%and Post,1376 59%, P = 0.88),and ginsenoside
Re(DI:Pre,7.463.0310
23andPost,5.961.1310
23,P=0.50;IS:Pre,117631%andPost,
134 6 34%, P = 0.44) groups. Ginsenosides Re, Rb1, and Rb2 were not detectable in plasma after
treatment with ginseng root extract or ginsenoside Re.
CONCLUSIONS—Oral ginseng or ginsenoside Re therapy does not improve b-cell function
or IS in overweight/obese subjects with impaired glucose tolerance or newly diagnosed diabetes.
Poor systemic bioavailability might be responsible for the absence of a therapeutic effect.
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I
t is estimated that 30% of the U.S.
population uses herbs for medicinal
purposes. Ginseng root extract (GRE)
is one of the most popular herbal prod-
u c t sa n di su s e db ym o r et h a n6m i l -
lion Americans each year. Ginseng has
beenapartofEasternmedicineformore
than 4,000 years and is purported to
prevent and treat diabetes. There are 11
commerciallyavailablespeciesofginseng,
but most reports evaluated Asian (Panax
ginseng) or American (Panax quinquefolius
L.) ginseng. The physiological effects of
ginseng are attributed to its triterpene
b-glycosides, known as ginsenosides;
more than 150 types of ginsenosides
have been identiﬁed (1).
Data from studies conducted in ani-
mal models and cell culture systems have
shown that ginseng extract and speciﬁc
ginsenosides have beneﬁcial effects on
insulin action and glucose metabolism.
Indiabeticmice,treatmentwithP.ginseng
radix or P. ginseng (Korean ginseng) stim-
ulates insulin release and improves glu-
cose tolerance and glycemic control
(2,3). Ginsenoside Re increases insulin
sensitivity (IS) in 3T3-L1 adipocytes (4)
and in ob/ob mice when administered in-
traperitoneally (2). It is not clear whether
consumption of ginseng or ginsenosides
affects IS and glucose homeostasis in hu-
mans. Most studies conducted in human
subjects only evaluated the effect of a sin-
gle oral dose of ginseng. Of these studies,
most (5–7), but not all (8), found that a
single dose lowered blood glucose area
underthecurve(AUC)duringanoralglu-
cose tolerance test (OGTT). Two studies
evaluated the effect of more prolonged
daily treatment with GRE or ginsenoside
Re on glycemic control in subjects with
type 2 diabetes (9,10). However, the in-
terpretation of the results from these
studies is unclear because of confound-
ing factors that could have inﬂuenced
the outcome measures, such as changes
in body weight and physical activity,
changes in diabetes medications, and
large drop-out rates.
The purpose of the current study was
to conduct a randomized, double-blind,
placebo-controlled trial to evaluate the
therapeutic potential of ginseng therapy
in overweight and obese subjects with
impaired glucose tolerance or newly di-
agnosed type 2 diabetes. Subjects were
randomized to 4 weeks of treatment
with GRE (Korean red ginseng), ginseno-
s i d eR e ,o rp l a c e b o .T h ee u g l y c e m i c -
hyperinsulinemic clamp procedure in
conjunction with stable isotopically la-
beled tracer infusion and the frequently
sampledmodiﬁedOGTT(FSOGTT)were
used to determine 1) oral glucose toler-
ance; 2) glucose and fatty acid kinetics;
3) insulin action in adipose tissue, liver,
and skeletal muscle; and 4) b-cell func-
tion.Becauseofvariabilityamongginseng
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ORIGINAL ARTICLEproducts, we conﬁrmed that our ginseng
extract and ginsenoside Re had biologi-
cal effects on insulin-mediated glucose
uptake in isolated muscle strips (D.H. Han
and J.O. Holloszy, submitted for pub-
lication).
RESEARCH DESIGN AND
METHODS
Study subjects
Fifteen overweight and obese adults (1
man, 14 women; age: 46 6 3y e a r s ,B M I
34 6 2k g / m
2) participated in this study.
Subjects were identiﬁed from the Wash-
ington University Volunteer for Health
database and completed medical evalua-
tion, blood tests, and a 2-h OGTT. Sub-
jects were required to have a new
diagnosis of type 2 diabetes or impaired
glucose tolerance and be overweight and/
or obese. Potential participants who had
any serious medical illnesses were ex-
cluded. Subjects had stable weight and
were sedentary for at least 3 months be-
fore the study. The study was approved
by the Human Research Protection Ofﬁce
of Washington University School of Med-
icine, and written informed consent was
obtained from all subjects.
Experimental protocol
Body composition. Body fat mass and
fat-free mass (FFM) were determined by
using dual-energy X-ray absorptiometry
(Hologic QDR 4500; Waltham, MA).
FSOGTT. Subjects were admitted to the
Clinical Research Unit at 0700 h after
subjects fasted overnight. A catheter was
inserted into a hand vein, which was
heated to 55°C by using a thermostati-
callycontrolledbox,toobtainarterialized
blood samples. Blood samples were
obtained to determine plasma glucose,
C-peptide, and insulin concentrations be-
fore (215 min and 0 min) and after (10,
20, 30, 60, 90, 120, 150, 180, 240, and
300 min) consuming a 75-gglucose drink.
Hyperinsulinemic-euglycemic clamp
procedure. In the evening on the day
of admission, subjects consumed a stan-
dard meal, containing 15 kcal/kg FFM at
;1800 h, and then fasted until comple-
tion of the clamp procedure. At 0600 h, a
catheter was inserted into an antecubital
vein of one arm for intravenous infusion,
and another catheter was inserted in a
vein in the opposite hand, which was
heated to 55°C by using a thermostatically
controlled box,toobtain arterializedblood
samples. At ;0700 h, a primed, continu-
ous infusion of [6,6-
2H2]glucose (infusion
rate: 0.25 mmol z min
21 z kg
21;p r i m i n g
dose: 22.5 mmol/kg), and a primed, con-
tinuous infusion of [1,1,2,3,3-
2H5]glycerol
(infusion rate 0.08 mmol z min
21 z kg
21;
priming dose 1.2 mmol/kg) was main-
tained for 7 h. At 210 min, insulin was in-
fused at a rate of 50 mU z m
2 body surface
area (BSA)
21 z min
21 (initiated with a
two-step priming dose of 200 mU z m
2
BSA
21 z min
21 for 5 min followed by
100 mU z m
2 BSA
21 z min
21 for 5 min)
for 210 min. Dextrose (20%), enriched
with [6,6-
2H2]glucose to ;2.5%, was in-
fused to maintain a plasma glucose con-
centration of 100 mg/dL. The infusion
rates of [
2H2]glucose and [
2H5]glycerol
were decreased by 75% during the clamp
procedure (from 210 to 420 min) to ac-
count for the decline in hepatic glucose
production and rate of glycerol release
into plasma. Blood samples were ob-
tained before the start of the infusions
to determinebackgroundplasmaglucose
and glycerol tracer-to-tracee ratios
( T T R s )a n de v e r y1 0m i nd u r i n gt h eﬁnal
30 min of the basal and clamp periods to
determine glucose, freefatty acid and insu-
lin concentrations, and substrate kinetics.
Intervention
After baseline studies were completed,
subjects were randomly assigned to 4
weeksoftreatmentwitheither:1)placebo
capsules (n =5 ) ;2) Korean red ginseng
extract (Spectrum Laboratories, Gardena,
CA) (3 g/day for2 weeksand then 8 g/day
for 2 weeks, n =5 ) ;3) ginsenoside Re
(AIPOP, Gangdown-Do, Korea) (250 mg/
day 3 2 weeks followed by 500 mg/day 3
2w e e k s ,n = 5) (Supplementary Data).
The relative content of ginsenoside Re in
the GRE used in this study was 13.7 6
1.4%, which is similar to the ginsenoside
Re content reported in previous studies
(8,11). We conﬁrmed that the batches of
ginseng and ginsenoside Re used in this
study had biological activity by demon-
strating that incubation with ginseng
and ginsenoside Re markedly improved
insulin-mediated glucose uptake in iso-
lated epitrochlearis muscles obtained from
diet-induced insulin resistant rodents
(D.H. Han and J.O. Holloszy, unpublished
ﬁnding) and rectus abdominus strips ob-
tained from obese subjects undergoing
gastric bypass surgery (D.H. Han and
J.O. Holloszy, unpublished observations).
Randomization to group assignment was
performed by The Barnes-Jewish Hospital
research pharmacist by using a ﬁxed ran-
domization scheme generated by the
Moses-Oakford algorithm, with a block
size of three and an allocation ratio of
1:1:1. All subjects, investigators, and lab-
oratorypersonnelperformingtheanalyses
were blinded to group allocation until
completion of all primary outcome meas-
ures. Subjects were seen once per week
by a member of the research team during
the intervention to assess compliance by
history and pill counts and to check for
potential adverse events. Subjects con-
sumed .90% of assigned pills, and no ad-
verse events were reported. At the end of
the4-weekperiod,allbaselinestudieswere
repeated. Subjects ingested their study
medication (placebo, ginseng, or ginseno-
side Re) in the morning 30 min before the
start of the FSOGTT and hyperinsulinemic-
euglycemic clamp procedure.
Sample processing and analyses
Plasmaglucose was measured by using an
automated glucose analyzer (YSI, Yellow
Springs Instruments, Yellow Springs,
OH). Plasma insulin and C-peptide con-
centrations were measured by radioim-
munoassay. Plasma glucose and glycerol
TTRs were determined using gas chro-
matography-mass spectrometry (12).
P l a s m ag i n s e n o s i d eR ec o n t e n tw a s
evaluated at every time point during the
FSOGTT. An aliquot of 100 mLp l a s m a
was acidiﬁed with perchloric acid (35%)
andcentrifuged at 1,100g for 30 min.The
supernatant was added to a solid-phase
cartridge (Oasis HLB 1 cc; Waters Corpo-
ration,Milford,MA).Afterthesamplewas
absorbed by the cartridge, the cartridge
was washed with 4 mL water. Ginseno-
sides were eluted with 1 mL 95% metha-
nolinwaterandevaporatedinaSpeedVac
(Savant Instruments, Inc., Farmingdale,
NY) at 40°C. The residue was reconstitu-
ted in 100 mL 95% methanol. After cen-
trifugation at 20,000g for 15 min,
ginsenoside Re, Rb1,a n dR b 2 content in
the supernatant was evaluated by liquid
chromatography/mass spectrometry, as de-
scribed previously (13). A standard curve
was generated using ginsenoside Re of
known concentration. This method has a
detection limit of 8.0 ng/mL (8.4 nmol/L),
which is the minimal concentration of
ginseng that is necessary to demonstrate
biological activity in vitro (4).
Calculations
FSOGTT. TotalAUCforglucose,insulin,
and C-peptide during the ﬁrst 120 min of
the FSOGTT were calculated by using the
trapezoidal method. Whole-body IS (Si)
wasestimatedfromtheFSOGTTbyusing
t h eo r a lg l u c o s em i n i m a lm o d e l ,w h i c h
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Ginseng and insulin sensitivitymeasures the overall effect of insulin to
stimulate glucose disposal (14). b-Cell
function was evaluated by determining
the disposition index (DI), which repre-
sents the insulin secretory response in re-
lationship to IS, calculated as the product
of the b-cell responsivity index (Fo)a n d
Si (15). DI could not be determined in
three subjects (two in the placebo group
and one in the ginsenoside Re group), be-
cause plasma samples from two subjects
were lost and our modeling program was
not able to adequately curve-ﬁtt h ed a t a
from one subject.
Tracer kinetics. Steele’se q u a t i o nf o r
steady-stateconditionswasusedtocalcu-
late glucose rate of appearance (Ra), glu-
cose rate of disappearance (Rd), and
glycerol Ra during the ﬁnal 30 min of
the basal period and the clamp (16). The
hepatic IS index was determined as the
product of the basal hepatic glucose pro-
duction rate and basal plasma insulin
concentration (17).
Statistical analyses
All outcome measures were analyzed by
u s i n gat h r e e - w a y( g r o u p3 condition)
ANOVA with repeated measures using a
332factorialdesigninwhichthegroups
areplacebo,ginsengextract,andginseno-
side Re and the conditions are basal and
high insulin periods during the hyperin-
sulinemic-euglycemic clamp. Signiﬁcant
F ratios from each analysis were followed
byposthoccomparisons bythe Neuman-
Keuls procedure, using the appropriate
error terms. A P value of #0.05 was con-
sidered statistically signiﬁcant. All data
are reported as means 6 SE.
The primary outcome of this study
was insulin-stimulated glucose uptake
during the hyperinsulinemic-euglycemic
clamp procedure. Based on our previous
data evaluating the reproducibility of
assessing glucose kinetics during a hyper-
insulinemic-euglycemic clamp procedure
(16), we estimated that ﬁve subjects in
each group would be needed to detect a
25% improvement in insulin-stimulated
glucose disposal, with a power of 0.8
and an a-value of 0.05. A treatment effect
of 25% was chosen because this is the ef-
fect often observed after weight loss (18)
or thiazolidinedione therapy (19). All val-
ues are means 6 SE.
RESULTS
Subject characteristics and
metabolic variables
Study subject characteristics and meta-
bolic variables before and after treatment
a r es h o w ni nT a b l e1 .B o d yw e i g h ta n d
body composition and metabolic varia-
bles did not change after the intervention
in any group.
FSOGTT
Insulin and glucose AUC during the ﬁrst
1 2 0m i na f t e ri n g e s t i o no ft h eg l u c o s e
load were not different between groups at
baseline and did not change after therapy
inanygroup (Fig.1AandC).Values forSi
(Fig. 1B)a ndD I( F i g .1 D)were not differ-
ent between groups at baseline and did
not change after the intervention.
Basal substrate kinetics
BasalglucoseRaaftertheinterventionwas
not different than values obtained before
intervention in the placebo (725 6 21
versus 682 6 33 mmol/min), ginseng
(865 6 69 versus 780 6 99 mmol/min),
and ginsenoside Re (635 6 69 versus
638 6 99 mmol/min) groups. Similarly,
glycerol Ra after the intervention was not
different in the placebo (156 6 8 versus
165 6 12 mmol/min), ginseng (250 6 42
versus 248 6 49 mmol/min), or ginseno-
sideRe(242625versus221622mmol/
min) groups. The hepatic IS index after
therapy was not different than values ob-
tained before therapy in the placebo, gin-
seng, and ginsenoside Re groups (Fig. 2A).
Hyperinsulinemic-euglycemic clamp
procedure
Meanplasmaglucose concentrationsdur-
ing the last 30 min of the insulin infusion
after treatment were the same as values
obtained before treatment in the placebo
(96 6 1a n d9 36 1 mg/dL), ginsenoside
Re (97 6 1a n d9 76 1 mg/dL), and gin-
seng (99 6 1a n d9 96 1m g / d L )g r o u p s .
Mean plasma insulin concentrations dur-
ingthelast30minofinsulininfusionafter
treatment were also the same as values
obtained before treatment in the placebo
(78 6 5an d766 7 mU/mL), ginsenoside
Re (88 6 7a n d8 96 7 mU/mL), and
ginseng (78 6 12 and 76 6 10 mU/mL)
groups.
Insulin infusion increased the rate of
glucose disposal in all groups, but the
percent increase above basal was not
affected by placebo, ginsenoside Re, or
ginseng therapy (Fig. 2B). Endogenous
glucose production rates decreased in all
groups during insulin infusion but the
relative suppression in glucose Ra did
not change with treatment in any group
(Fig. 2C). The decrease in glycerol Ra dur-
ing insulin infusion was also the same after
as before therapy in all groups (Fig. 2D).
Plasma ginsenoside concentration
Plasma concentrations of ginsenoside Re,
Rb1,andRb 2werenotdetectableinblood
Table 1—Study subject characteristics and metabolic variables before and after treatment
Before After Before After Before After
Sex (male/female) 1/4 — 0/5 — 0/5 —
Race (African American/Caucasian) 2/3 — 1/4 — 3/2 —
Weight (kg) 88 6 89 0 6 79 8 6 11 98 6 11 89 6 49 1 6 5
BMI (kg/m
2)3 1 6 13 2 6 13 5 6 33 5 6 33 6 6 23 7 6 2
Fat mass (% body wt) 40 6 34 0 6 44 0 6 54 0 6 44 3 6 24 3 6 2
Glucose (mg/dL) 94.1 6 1.8 95.6 6 3.2 96.0 6 6.6 98.2 6 3.7 94.5 6 2.4 95.5 6 4.3
Insulin (mU/mL) 7.3 6 1.4 8.0 6 1.8 11.1 6 4.0 12.1 6 3.5 11.2 6 1.3 11.9 6 2.4
HbA1c (%) 5.9 6 0.2 5.9 6 0.1 5.5 6 0.1 5.7 6 0.1 5.8 6 0.8 5.9 6 0.1
Total cholesterol (mg/dL) 214 6 21 202 6 15 164 6 27 165 6 27 206 6 32 204 6 26
Triglyceride (mg/dL) 130 6 24 120 6 27 135 6 36 128 6 29 126 6 23 139 6 31
HDL cholesterol (mg/dL) 47 6 54 6 6 54 6 6 64 4 6 55 2 6 65 0 6 6
LDL cholesterol (mg/dL) 140 6 20 132 6 12 88 6 20 96 6 21 143 6 27 126 6 19
Data are means 6 SE.
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Reeds and Associatessamples obtainedfrom30minto 6hafter
ingesting the morning dose of ginseng or
ginsenoside Re during the day of the
FSOGTT and from 30 min to 7.5 h after
ingesting the morning dose of ginseng or
ginsenoside Re during the day of the
hyperinsulinemic-euglycemic clamp pro-
cedure. The method used to assess ginse-
noside concentrations has a lower limit of
detection of 8.0 ng/mL (8.4 nmol/L),
which is below the minimal concentra-
tion of ginsenoside Re and Rb1 necessary
to increase IS in vitro (4).
CONCLUSIONS—Ginseng is a popu-
lar herbal therapy that is purported to
be effective in both the prevention and
treatment of diabetes. Data from studies
conducted in animal models have identi-
ﬁed ginsenoside Re as a component of
ginseng that affects IS and improves
glycemic control (2). Therefore, we con-
ducted a double-blind, randomized,
placebo-controlled study to determine
whether treatment with ginseng or
ginsenoside Re improves oral glucose tol-
erance,b-cellfunction,andISinhumans.
Only subjects with impaired glucose tol-
erance or newly diagnosed type 2 diabe-
tes,whopresumablyhavemorereversible
metabolic dysfunction, were studied to
increase our ability to detect a beneﬁcial
effect of therapy. Moreover, we used spe-
ciﬁc sources of ginseng and ginsenoside
Rethatwefoundimprovedskeletalmuscle
IS in vitro in rodent and human muscle
strips. Our data demonstrate that 4 weeks
of oral ginseng and ginsenoside Re therapy
do not improve oral glucose tolerance,
b-cell function, or multiorgan IS. These
results refute the popular notion that in-
gestion of ginseng and its putative active
ginsenoside component has beneﬁcial
metaboliceffectsonglucosehomeostasis.
Data from studies conducted in 3T3-
L1 adipocytes and in obese, insulin-
resistant rodent models have found that
GRE and several ginsenoside species (Re,
Rb1) improve insulin-stimulated glucose
disposal (2,20). In most of these animal
studies, ginseng and ginsenosides were
given intraperitoneally. Oral administra-
tion of ginseng or ginsenosides has also
beenreportedtoimproveoralglucosetol-
erance and increase insulin-stimulated
glucose disposal (21,22). However, the
results from these studies are confounded
by concomitant weight loss, so it is un-
clear whether the improvements in IS oc-
curred because of weight loss or because
of the insulin-sensitizing properties of
ginsenosides. Few studies have evaluated
the effect of ginseng in human subjects,
and the interpretation of data from these
s t u d i e si sd i f ﬁcult because of differences
in experimental design and contradictory
results among studies. A single dose of
oral ginseng given ;40 min before glu-
cose ingestion reduced the glucose AUC
during an OGTT by ;20% in some stud-
ies (23) but had no beneﬁcial effect in
others (8). Longer term oral ginseng ther-
apy was evaluated in subjects with type 2
diabetes in two studies. In one study, gin-
seng treatment (6 g/day for 12 weeks)
lowered plasma insulin concentration
but did not change HbA1c (10), whereas
ginseng treatment (100–200mg/day for8
weeks) in the other study was associated
with a decrease in fasting plasma glucose
concentration (9). However, the interpre-
tation of the results from both studies is
Figure1—Glucose(A)andinsulin(C)AUCobtainedduringtheﬁrst2hofthe5-hFSOGTT,and
IS (B) and DI (D), assessed by the FSOGTT before (white bars) and after (black bars) treatment
with placebo, ginseng, or ginsenoside Re. Values are means 6 SE.
Figure 2—Hepatic IS index (A), insulin-mediated increase in glucose Rd (B), insulin-mediated
suppression of glucose Ra (C), and insulin-mediated suppression glycerol Ra (D) during the
hyperinsulinemic-euglycemic clamp procedure before (white bars) and after (black bars)
treatment with placebo, ginseng, or ginsenoside Re therapy. Values are means 6 SE.
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Ginseng and insulin sensitivityconfounded by either a large drop-out
rate (10) or concomitant weight loss (9).
Oralginsengtherapy(3g/dayfor14days)
did not improve insulin-mediated glu-
cose disposal, assessed by using the
hyperinsulinemic-euglycemic clamp pro-
cedure, in subjects with indinavir-
inducedskeletalmuscleinsulinresistance
(24).
Wewereunabletodetectginsenoside
Re, Rb1,o rR b 2 in plasma in our subjects,
even though they were prescribed large
daily oral doses of ginseng and ginseno-
side Re for 30 days and ingested the last
dose ;30 min before a series of blood
samples were obtained to assess blood
concentrations. The method we used to
measure ginsenoside Re, Rb1,o rR b 2
has a threshold of detection of 8 ng/mL,
which is below the minimal concentration
necessary for biological activity in vitro
(4). Therefore, our results suggest that
g i n s e n o s i d eR ei sp o o r l ya b s o r b e df r o m
oral ingestion of ginseng or ginsenoside
Re itself. The limited systemic bioavail-
ability of ginseng Re in our subjects helps
explainthe discrepancy between our ﬁnd-
ings and the positive effects observed in
studies that involved intraperitoneal gin-
seng injection (2) or in vitro incubation
with ginseng (4,20). Data from phar-
macokinetic studies conducted in rodents
and people have found that absorption of
ginseng metabolites is poor after oral in-
gestion (13,25). Plasma ginseng or ginse-
noside concentrations were not reported
in previous studies that found metabolic
beneﬁts of ginseng therapy in study sub-
jects. We are aware of only one study that
evaluated oral ginsenoside absorption in
human subjects (13). This study was con-
ducted in two subjects who were studied
for 12 h after ingesting GRE. Ginsenoside
Rb1 and Rb1 were detected at very low
levels in plasma (;5 nmol/L) in one sub-
ject, but ginseng components were not
detected in the other subject. Very low
levels of ginsenoside Re were found in
urine for up to 3 h after ingestion. The
poor absorption of orally ingested ginse-
nosides is likely related to its saponin ring
structure,whichispoorlysolubleinaque-
ous solutions. In addition, protopanax-
triols (e.g., ginsenoside Re) are rapidly
hydrolyzed to ginsenoside Rb1 in mildly
acidic conditions, such as in the stomach,
suggesting that the bioavailability of orally
administered ginsenoside Re is particu-
larly poor. Our results, in conjunction
with data from other studies, suggest that
oral ginsenoside products are too poorly
absorbed to provide adequate systemic
availability to inﬂuence metabolic func-
tion. We cannot exclude the possibility
that other ginsenosides and their metabo-
lites or nonginsenoside components of
GRE are bioavailable when given enterally.
Although it is possible that our study
missed a therapeutic effect of ginseng or
g i n s e n o s i d eR eb e c a u s eo ft h es m a l ln u m -
ber of study subjects, we believe that this
is unlikely. We used the hyperinsuline-
mic-euglycemicclampprocedure,incon-
junction with stable isotopically labeled
tracer infusion, to evaluate IS. We have
demonstrated that this procedure is very
sensitive and reproducible (16) and
would allow us to detect a 25% improve-
ment in insulin-stimulated glucose dis-
posal in the current study with a power
of 0.8. Our data did not even detect a
trend toward treatment-induced im-
provement in any of our study outcome
measures. Ginsenoside composition varies
between commercially available products,
so our study cannot eliminate the possibil-
ity that other ginseng products could have
metabolic beneﬁts.
In summary, despite the popular use
of ginseng products to improve glucose
homeostasis and treat type 2 diabetes, we
found no evidence that oral ginseng or
ginsenoside Re therapy improves b-cell
function or IS in subjects with impaired
glucose tolerance or newly diagnosed
type 2 diabetes. Although parenteral gin-
seng and ginsenoside Re can markedly
enhance insulin action in animal models,
our data suggest that minimal bioavail-
ability after oral ingestion limits its thera-
peutic efﬁcacy in people.
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